# Alkeus Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alkeus-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.alkeuspharma.com
- Total disclosed funding: $150M
- Latest round: Series B (Jun 5, 2023)
- Investors on record: 4

## About

Based in Massachusetts, US, and founded in 2010 by President and Chief Executive Officer Leonide Saad and co-founders Ilyas Washington, Alkeus Pharmaceuticals Inc. operates as a biotechnology company providing treatment of degenerative eye diseases for patients. In June 2023, Alkeus Pharmaceuticals Inc. raised USD 150 million in Series B funding led by Bain Capital, with participation from Sofinnova Investments, TCG Crossover Management, and Wellington Management.

Alkeus Pharmaceuticals Inc. provides treatment of Stargardt disease of the eye known as Gildeuretinol (ALK-001), which is a medicine in clinical development to selectively address the underlying mechanism of Stargardt disease, by reducing the rate of vitamin A dimerization in the eye. The company offers therapy for genetic and autosomal recessive diseases.

## Funding rounds

- Series B, Jun 5, 2023, $150M — Bain Capital, Sofinnova Investments, Wellington Management, TCG Crossover Management

## Investors

- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series B
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series B
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series B
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series B